Physician profile
Cindy Wang
NPI 1679552525
$3,441.20
in general payments reported to CMS, 2019-2025
20 companies · $813 in 2025
The $813 reported for 2025 was more than what 88% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $232 · 2020: $197 · 2021: $416 · 2022: $750 · 2023: $497 · 2024: $536 · 2025: $813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,820 · Entertainment: $26.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,819.76 |
| Entertainment | $26.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $677.04 | 2019-2025 | Rocklatan, Tryptyr, Eysuvis |
| Sun Pharmaceutical Industries INC. | $481.88 | 2019-2025 | Cequa |
| Oyster Point Pharma, INC. | $314.83 | 2022-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $276.56 | 2022-2025 | Vyzulta, Xiidra, Miebo |
| Aerie Pharmaceuticals, INC. | $253.41 | 2019-2021 | |
| Allergan, INC. | $220.10 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $212.67 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $149.52 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $149.39 | 2019-2021 | |
| Biotissue Holdings INC. | $145.75 | 2024-2025 | |
| Abbvie INC. | $112.27 | 2022-2024 | Lumigan |
| Apellis Pharmaceuticals, INC. | $83.50 | 2025 | Syfovre |
| Kala Pharmaceuticals, INC. | $67.26 | 2020-2022 | |
| Shire North American Group INC | $57.15 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $53.00 | 2022-2023 | Acuvue |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $50.87 | 2024-2025 | Iyuzeh |
| Dompe US, INC. | $46.73 | 2024-2025 | Oxervate |
| Rayner Intraocular Lenses Limited | $34.60 | 2023 | Rayone Emv, Omidria, Rayone Aspheric |
| Harrow Eye, LLC | $28.46 | 2025 | Vevye |
| Optos, INC. | $26.21 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cindy Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.